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P-cadherin expression in glandular lesions of the uterine cervix detected by liquid-based
cytology
Objective: To study P-cadherin aberrant expression as a possible marker for cervical adenocarcinomas in
cytological samples.
Methods: We studied P-cadherin immunoexpression in liquid-based cervical cytology samples of biopsy-proven
cervical lesions.
Results: We found a statistically significant correlation between P-cadherin expression and a cytological
diagnosis of malignancy, either glandular or squamous (P < 0.0001). Twenty-two of 33 malignant cases showed
P-cadherin membrane staining. None of the 30 benign cases tested showed membrane staining, but three of them
displayed an aberrant nuclear P-cadherin expression.
Conclusions: We concluded that P-cadherin can be used to discriminate between malignant and benign cervical
cytological specimens, but not to discriminate glandular from squamous lesions.
Keywords: P-cadherin, uterine cervix, glandular lesions, liquid-based cytology
Introduction
Cervical adenocarcinoma is increasing in incidence
worldwide, as well as in the relative proportion
between this lesion and squamous cell carcinoma,
particularly among young women.1–4 However, in
contrast to screening for squamous lesions of the
cervix, cervical smears have not been shown to reduce
the incidence of adenocarcinoma.5–8 Difficulties in the
interpretation of cytological findings may be respon-
sible for both overdiagnosis and underdiagnosis of
glandular lesions. For example, the diagnosis of
atypical glandular cells of undetermined significance
(AGUS) is associated with a wide range of significant
pathologies, many of them being considered squa-
mous lesions.9,10 Patients with AGUS are usually
referred for colposcopic examination and other pro-
cedures, such as endometrial aspiration, endocervical
curettage, as well as cervical conization. Based on this
fact, pathologists are required to report not only
whether the smears favour neoplastic changes, but
also the origin of the abnormal cells.11,12
Liquid-based cervical cytology (LBC) does offer
some improvement in the detection rate of glandular
abnormalities; moreover, molecular markers are also
useful in distinguishing cervical adenocarcinoma from
benign mimics.4,13 Immunohistochemical staining of
MIB-1, bcl-2, CEA and p53 have shown potential in
discriminating between cervical glandular abnormal-
ities.14–18 Recently, the use of p16INK4a immunocyto-
chemical reaction has emerged as an adjunct tool to
distinguish cellular alterations that predict high-grade
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lesions,4,13 alone or associated with Ki-67, a cell cycle
marker.14 p16 protein is a cyclin-dependent kinase
inhibitor, the increased levels of which appear to be
related to high-risk HPV infection. Therefore, its
overexpression is believed to address the nature of
lesions of undetermined significance.4,11,13 Nieh
et al.13 studied the p16INK4a expression in cervical
smears with AGUS and found that it was a highly
sensitive and specific marker for neoplasia. Addition-
ally, Akpolat et al.14 have also found an association
between the expression of p16INK4a and Ki-67 to
identify high-grade and malignant lesions.
Recently, P-cadherin expression has been thought
to be a useful tumour prognostic marker in some
situations.18–23 P-cadherin-related tumour progres-
sion was observed in ovarian cancer,19 high-grade
breast carcinoma20,21 and uterine cervix intraepithel-
ial lesions.18,22
P-cadherin belongs to a superfamily of calcium-
dependent cell–cell adhesion glycoproteins expressed
on the cell surface membrane.24 These molecules
are thought to participate in several pathological
conditions, such as cancer, and in some biological
processes, including embryo development.25 Cadhe-
rins have also been implicated in a number of
signalling pathways that regulate cellular activities,
and it seems that the information received from
cell–cell signalling, cell–matrix signalling, and
growth factor signalling determines ultimate cellular
phenotype and behaviour of normal or malignant
cells.24–26
More interestingly, P-cadherin aberrant expression
was reported as a possible marker for glandular
invasive malignancy of the uterine cervix.18 The
authors studied archival paraffin block samples and
showed that P-cadherin, normally confined to basal
epithelial cells and not observed in benign glands,
was aberrantly expressed in 96% (23 of 24 cases) of
invasive adenocarcinomas and in 25% (two of eight
cases) of adenocarcinoma in situ.
Therefore, the use of this molecular marker in the
discrimination between malignant and benign glandu-
lar lesions encouraged us to study P-cadherin expres-
sion in cervical LBC. To achieve this goal, we selected
cytological samples of in situ and invasive biopsy-
proven adenocarcinoma, intraepithelial and invasive
squamous lesions, and negative cases with normal
squamous and glandular cells, in order to determine
whether P-cadherin could be used as an adjunct
tool in assessing glandular atypias. To the best of
our knowledge this is the first report focusing on
P-cadherin expression in uterine glandular lesions
assessed by LBC.
Materials and methods
Cytology collection
Archival cytological samples were retrieved from the
files of the Department of Pathology of the Federal
University of Goia´s, Brazil. The samples had been
previously collected at Arau´jo Jorge Hospital, Goia´s,
Brazil, during the year 2002, and were selected
according to the following criteria: cases with a
biopsy-proven cytological diagnosis of adenocarcino-
ma and related HPV-induced lesions (squamous
intraepithelial lesions, adenosquamous carcinoma);
and cases where normal glandular cells were numer-
ous, with no evidence of uterine disease to use as
control cases. The cytological diagnoses were reported
using the 2001 Bethesda System.27
LBC preparation
The cervical specimens for LBC (DNA-CITOLIQ
System) were collected with a cervical brush and
placed in a tube containing 1 ml of Universal Collec-
tion Medium (UCM) (Digene Co., Gaithersburg, MD,
USA). The DNA-CITOLIQ System consists of an
aluminium instrument, the PREPGENE, which holds
a slide holder (LAMIGENE) and a polycarbonate filter
holder (FILTROGENE), with 25 mm diameter mem-
branes (5 lm pore size). Twelve slides are prepared
simultaneously. Briefly, the tube is vortexed for
15 seconds, individually, at high speed, and 200 ll of
the UCM specimen is put onto the polycarbonate
membrane, spreading the liquid uniformly on the
entire membrane surface. Then, the PREPGENE lid is
locked for 10 seconds. During this step, an imprint of
the cells is carried from the membrane to the glass slide.
Immunocytochemistry protocol
All cases were manually processed according to the
streptavidin–biotin–peroxidase technique and using a
commercial detection system (Ultra Vision Detection
System; Lab Vision Corporation, Fremont, CA, USA),
following the manufacturer’s instructions. Cytological
specimens, previously stained by the Papanicolaou
technique, were hydrated and heat-induced antigen
retrieval was done using EDTA solution, pH 8.0 (Lab
Vision Corporation) in a 98 C water-bath, for
P-cadherin in cervical glandular lesions 89
Cytopathology 2005, 16, 88–93 ª 2005 Blackwell Publishing Ltd
20 minutes. After cooling at room temperature for
20 minutes, endogenous peroxidase activity was
blocked by treating the slides with 3% peroxide/
methanol solution for 10 minutes. Non-specific
staining was eliminated by incubation with normal
serum (UltraVison Block; Lab Vision Corporation)
for 20 minutes. The primary monoclonal antibody to
the extracellular domain of P-cadherin (clone 56;
BD- Transduction Laboratories, Lexington, KY,
USA), diluted 1:50, was applied to the slides and
incubated overnight at room temperature in a
humid chamber. After washing with PBS-Tween,
the slides were incubated with a biotin-labelled
secondary antibody followed by streptavidin–biotin–
complex also from Lab Vision. The samples were
then stained with a solution of 3,3-diaminobenzi-
dine tetrahydrochloride (DAB) (Lab Vision Corpora-
tion), counterstained with Mayer’s haematoxylin
(Merck, Darmstadt, Germany), dehydrated and
mounted.
Formalin-fixed, paraffin-embedded positive and
negative controls were included in each run. Normal
human skin tissue samples were used as positive
control for P-cadherin expression (continuous
membrane staining of the proliferative/basal cell
layer).
P-cadherin immunocytochemical evaluation
The expression of P-cadherin was evaluated by light
microscopy as positive or negative, giving particular
attention to the cellular localization of the positive
reaction. Positive immunocytochemical reaction
was defined as a well-decorated, brownish mem-
brane staining, with a faint residual cytoplasmic
staining.
Predictive value of P-cadherin expression
The predictive negative and positive values of
P-cadherin positive reaction was calculated using the
following formulas: NPV ¼ True negative (TN)/TN +
false negative · 100% and PPV ¼ true positive
(TP) ¼ TP + false positive · 100%, or 22/22 ¼ 100%.
HPV status
The HPV status of the cases had been previously
evaluated using the Hybrid Capture II and PCR
methodology. The results were correlated with
P-cadherin immunoreaction.
Results
LBC slides of 33 biopsy-proven cases were selected for
P-cadherin immunocytochemical reactions. The pos-
itive immunoreactions were clearly demonstrated in
clusters of squamous and/or glandular atypical cells
(Figure 1). The overall distribution of P-cadherin
reactions in positive cytology is depicted in Table 1.
The cases were classified as follows: one low-grade
squamous intraepithelial lesion (LSIL), one atypical
squamous lesion (ASC-H), seven high-grade squa-
mous intraepithelial lesions (HSIL), two adenosqua-
mous carcinoma, five squamous cell carcinomas
(SCC), 13 adenocarcinomas in situ and four invasive
adenocarcinomas. P-cadherin expression was
observed in 22 of the 33 (66.6%) analysed cases:
nine squamous and 11 glandular lesions (Figure 1).
Eleven cases (five squamous and six glandular lesions)
did not show P-cadherin expression. The two cases of
adenosquamous carcinoma were both positive for
P-cadherin. Normal squamous and metaplastic cells
were not stained by P-cadherin.
Thirty negative cases for malignancies and/or intra-
epithelial lesions were retrieved from the pathology
files. All of them were negative for P-cadherin
membrane staining; however three of 30 cases
(10%) showed a nuclear pattern of expression, and
were considered as negative cases.
The correlation between P-cadherin expression and
the diagnosis of a malignant lesion was statistically
significant (Fisher’s exact test: P < 0.0001) (Table 2).
Figure 1. P-cadherin expression in a cervical adenocarcin-
oma cytological specimen. Note the intense membrane
staining in the neoplastic cells (streptavidin–biotin–peroxi-
dase, ·400).
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The expression of P-cadherin was observed only in the
specimens with a previous cytological diagnosis of
malignant glandular or squamous lesion, while all the
cases previously diagnosed as benign did not express
P-cadherin. The predictive negative and positive
values of P-cadherin expression to detect malignancy
were 73% (30/30 + 11 · 100%) and 100% (22/22 +
0 · 100%).
From the 33 cases with HPV-related lesions, 31
(94.0%) tested positive for oncogenic HPV with
Hybrid Capture II methodology. The HPV status of
the 30 negative control-cases tested with PCR meth-
odology found four cases (13.3%) were positive for
oncogenic HPV (two HPV-16, one HPV-18 and one
HPV-53). Table 3 summarizes these findings and also
includes the correlation with P-cadherin expression.
Discussion
The diagnosis of adenocarcinoma in cytological mater-
ial has become more common, mainly due to the
increasing incidence of the disease, better endocervi-
cal sampling devices being used, and the morpholo-
gical criteria for this diagnosis have been defined
better and refined.5 However, there is still a significant
variability in the interpretation of glandular lesions in
cytology specimens. The use of additional HPV testing
in atypias of glandular origin is particularly suggested
for these cases.11,28 Efforts to improve the recognition
of adenocarcinoma, primarily adenocarcinoma in situ,
are a necessary caveat strategy to avoid incorrect
categorization of such lesions in cervical smear
examination.29,30
Recently, new parameters to evaluate cervical
lesions have been studied.31–34 Accordingly, the pre-
servative media of LBC systems are promising tools
where immunocytochemical panels might be per-
formed in order to optimize the cytological analysis. In
particular p16 is presumed to be a specific biomarker
for high-risk HVP in women with cervical genital
malignant and premalignant squamous lesions and is
overexpressed in cervical adenocarcinoma (both
in situ and invasive).31 Additionally, Ki-67 expression
Table 1. Distribution of P-cadherin expression and the
positive cytological diagnoses
Case P-cadherin expression Cytological diagnoses
1 Negative LSIL
2 Negative SCC
3 Negative HSIL
4 Negative HSIL
5 Negative Adenocarcinoma in situ
6 Negative Invasive adenocarcinoma
7 Negative Invasive adenocarcinoma
8 Negative Adenocarcinoma in situ
9 Negative HSIL
10 Negative Adenocarcinoma in situ
11 Negative Adenocarcinoma in situ
12 Positive HSIL
13 Positive Adenocarcinoma in situ
14 Positive HSIL
15 Positive Adenocarcinoma in situ
16 Positive Invasive adenocarcinoma
17 Positive Adenosquamous carcinoma
18 Positive Adenocarcinoma in situ
19 Positive SCC
20 Positive SCC
21 Positive ASC-H
22 Positive HSIL
23 Positive HSIL
24 Positive Adenocarcinoma in situ
25 Positive Invasive adenocarcinoma
26 Positive SCC
27 Positive Adenocarcinoma in situ
28 Positive Adenocarcinoma in situ
29 Positive Adenocarcinoma in situ
30 Positive SCC
31 Positive Adenocarcinoma in situ
32 Positive Adenosquamous carcinoma
33 Positive Adenocarcinoma in situ
LSIL, low-grade squamous intraepithelial lesion; HSIL, high-
grade squamous intraepithelial lesion; SCC, squamous cells
carcinoma; ASC-H, atypical squamous lesion favouring high-
grade lesion.
Table 2. Correlation between P-cadherin (P-cad) expression
and the samples cytological diagnoses
Benign Malignant Total
P-cad negative 30 (100%) 11 (33.33%) 41
P-cad positive 0 (0.0%) 22 (66.67%) 22
Total 30 (100%) 33 (100%) 63
Fisher’s exact test: P < 0.0001.
Table 3. Correlation between P-cadherin (P-cad) expression
and HPV status correlated with cytological diagnoses
HPV negative HPV positive
Negative cytology (n ¼ 30)
P-cad negative 26 (86.7%) 4 (13.3%)
P-cad positive 0 0
Positive cytology (n ¼ 33)
P-cad negative 0 11 (33.4%)
P-cad positive 2 (6.0%) 20 (60.6%)
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in intraepithelial lesions is a strong predictor of
progression and seems to increase progressively in
parallel with increasing aggressiveness of the
lesions32; besides that, it also appears correlated with
p16 expression.33 Concomitant p53 and p16 overex-
pression in patients with high-risk HPV infection is
strongly associated with adenocarcinoma status.34
The premise of our study was to evaluate
P-cadherin expression in LBC specimens, essentially
to investigate the value of this molecular marker in
cytological examination of cervical samples.
Aberrant P-cadherin is associated with a prolifera-
tive phenotype related to ulceration and neoplastic
transformation, which may confer a survival advant-
age to these cells; but the relative functional role of
P-cadherin and the molecular mechanisms underlying
P-cadherin/catenin interactions have yet to be eluci-
dated.35 As P-cadherin is known to be expressed in
various tissues during embryogenesis, and also in the
proliferative cells of normal epithelia, the expression
of P-cadherin in carcinomas may be an oncofoetal
phenomenon and/or may reflect its marked prolifer-
ative potential.36
The regulation of cadherin expression was previ-
ously reported in squamous intraepithelial lesions
suggesting that the progression of such lesions was
characterized by the gradual suppression of E-cadh-
erin expression while P-cadherin became predomin-
ant.22 Subsequently, P-cadherin evaluation was
suggested for endocervical lesions as a potential
marker of malignancy.18
We found a statistically significant correlation
between P-cadherin expression and a previous cyto-
logical diagnosis of malignancy, either glandular or
squamous, including intraepithelial squamous lesions.
On the other hand, we observed an inverse correla-
tion between the expression of this molecular marker
and the benign samples (classified as negative for
intraepithelial lesion or other malignancies by the
2001 Bethesda System27). P-cadherin can be used to
discriminate between malignant and benign cervical
cytological specimens, with predictive positive and
negative values of 100% and 73%, respectively.
However, P-cadherin positivity does not allow dis-
crimination between glandular and squamous lesions.
Likewise, negative status for oncogenic HPV infec-
tion strongly correlated with negative cytology and
negative P-cadherin immunoreactivity (86.7%). Con-
versely, positive HPV status correlated with positive
cytology and positive P-cadherin immunoreactivity
in 60.6%.
We also found an unusual P-cadherin nuclear
expression in normal endocervical cells in three of
the 30 negative samples. This staining pattern has
never been described for P-cadherin, in either benign
cells or malignant lesions. Whether this staining
pattern represents a real nuclear localization of
P-cadherin or a cross-reaction with other nuclear
factors, remains to be clarified. E-cadherin nuclear
expression was observed by Han et al.37 in Merckel cell
carcinomas; however, these authors, did not elucidate
this unexpected finding also.
In conclusion, the improved morphological details
of cervical glandular lesions provided by LBC, associ-
ated with an immunocytochemical search for the
expression of molecular markers, such as P-cadherin,
p16, p53 and Ki-67, could minimize the difficulties in
interpretation of glandular and squamous lesions of
undetermined significance.
References
1. Waggoner SE. Cervical cancer. Lancet 2003;361:2217–25.
2. Baalbergen A, Ewing-Grham PC, Hop WCJ, Struijk P,
Helmerhorst TJM. Prognostic factors in adenocarcinoma
of the uterine cervix. Gynecol Oncol 2004;92:262–7.
3. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising
incidence of adenocarcinoma relative to squamous cells
carcinoma of the uterine cervix in the United States: a
24-year population-based study. Gynecol Oncol
2000;78:97–105.
4. Schorge JO, Lea JS, Elias KJ et al. P16 as a molecular
biomarker of cervical adenocarcinoma. Am J Obstet Gynecol
2004;190:668–73.
5. Renshaw AA, Mody DR, Lozano RL et al. Detection of
adenocarcinoma in situ of the cervix in Papanicolaou
tests. Comparison of diagnostic accuracy with other high-
grade lesions. Arch Pathol Lab Med 2004;128:153–7.
6. Nanda K, McCrory DC, Myeres ER, Bastian LA, Hassel-
blad V et al. Accuracy of the Papanicolaou test in
screening for and follow up of cervical cytologic abnor-
malities: a systematic review. Ann Intern Med
2000;132:810–9.
7. Moriaty AT, Wilbur D. Those gland problems in cervical
cytology: faith or fact? Observations from the Bethesda
2001 terminology conference. Diagn Cytopathol
2003;28:171–4.
8. Segal A, Frost FA, Miranda A, Fletcher C, Sterrett GF.
Predictive value of diagnoses of endocervical glandular
abnormalities in cervical smears. Pathology 2003;35:198–
203.
9. Selvaggi S. Cytologic features of high-grade squamous
intraepithelial lesions involving endocervical glands in
ThinPrep cytology. Diagn Cytopathol 2002;26:181–5.
A. Longatto Filho et al.92
Cytopathology 2005, 16, 88–93 ª 2005 Blackwell Publishing Ltd
10. Wright VC. Cervical squamous and glandular intraepit-
helial neoplasia: identification and current management
approaches. Salud Publica Mex 2003;45:S417–29.
11. Bekkers RLM, Bulten J, Wiersma-van Tilburg A et al.
Coexisting high-grade glandular and squamous cervical
lesions and human papillomavirus infections. BJM
2003;89:886–90.
12. Tam KF, Cheung ANY, Liu KL et al. A retrospective review
on atypical glandular cells of undetermined significance
(AGUS) using the Bethesda 2001 classification. Gynecol
Oncol 2003;91:603–7.
13. Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of
p16INK4a in Pap smears containing atypical glandular cells
from the uterine cervix. Acta Cytol 2004;48:173–80.
14. Akpolat I, Smith DA, Ramzy I, Chirala M, Mody DR. The
utility of p16INK4a and Ki-67 staining on cell blocks
prepared from residual thin-layer cervicovaginal material.
Cancer Cytopathol 2004;102:42–9.
15. Cameron RI, Maxwell P, Jenkins D, McCluggage WG.
Immunohistochemical staining with MIB1, bcl-2, and p16
assists in the distinction of cervical glandular intraepit-
helial neoplasia from tubo-endometrial metaplasia, endo-
metriosis and microglandular hyperplasia. Histopathology
2002;41:313–21.
16. Cina SJ, Richardson MS, Austin RM, Kurman RJ.
Immunohistochemical staining for Ki-67 antigen,
carcinoembryonic antigen, and p53 in the differential
diagnosis of glandular lesions of the cervix. Mod Pathol
1997;10:176–80.
17. Zarka TA, Han AC, Edelson MI, Rosenblum NG. Expres-
sion of cadherins, p53, and BCL2 in small cell carcinoma
of the cervix: potential tumor suppressor role for
N-cadherin. Int J Gynecol Cancer 2003;13:240–43.
18. Han AC, Edelson MI, Soler AP et al. Cadherin expression
in glandular tumors of the cervix. Aberrant P-cadherin as
a possible marker of malignancy. Cancer 2000;89:2053–8.
19. Patel IS, Madan P, Getsios S, Bertrand MA, MacCaman
CD. Cadherin switching in ovarian cancer progression. Int
J Cancer 2003;106:172–77.
20. Paredes J, Milanezi F, Viegas L, Amendoeira I, Schmitt F.
P-cadherin expression is associated with high-grade
ductal carcinoma in situ of the breast. Virchows Arch
2002;440:16–21.
21. Paredes J, Milanezi F, Reis-Filho JS et al. Aberrant
P-cadherin expression: is it associated with estrogen-
independent growth in breast cancer? Pathol Res Pract
2002;198:795–801.
22. Boer CJ, van Dorst E, van Krieken H et al. Changing roles
of cadherins and catenins during progression of squamous
intraepithelial lesions in uterine cervix. Am J Pathol
1999;155:505–15.
23. Chen GTC, Tai CT, Yen LS, Yang TC, Tsai HD. Identifica-
tion of the cadherin subtypes present in the human
peritoneum and endometriotic lesions: potential role for
P-cadherin in the development of endometriosis. Mol
Reprod Dev 2002;62:289–94.
24. Vleminckx K, Kemler R. Cadherins and tissue formation.
Bio Essays 1999;21:211–20.
25. Wheelock MJ, Johnson KR. Cadherins as modulators of
cellular phenotype. Annual Review of Cell and Dev Biol
2003;19:207–35.
26. Zigmond S. Formin adherens junctions. Nature Cell Biol
2004;6:12–14.
27. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda
System. Terminology for reporting results of cervical
cytology. JAMA 2002;287:2114–9.
28. Krane JF, Lee KR, Sun D, Yuan L, Crum CP. Atypical
glandular cells of undetermined significance. Am J Clin
Pathol 2004;121:87–92.
29. Oliveira ERZM, Derchain SFM, Rabelo-Santos SH et al.
Detection of high-risk human papillomavirus (HPV) DNA
by hybrid capture II in women referred due to atypical
glandular cells in the primary screening. Diagn Cytopathol
2004;31:19–22.
30. Nonogaki S, Wakamatsu A, Longatto Filho A et al. Hybrid
Capture II and polymerase chain reaction for identifying
HPV infections in samples collected in a new collection
medium: a comparison. Acta Cytol 2004;48:514–20.
31. Klaes R, Friedrich T, Spitkovsky D et al. Overexpression of
p16INK4A as a specific marker for dysplastic and neoplastic
epithelial cells of the cervix. Int J Cancer 2001;92:276–84.
32. Maeda MYS, Simo˜es M, Wakamatsu A et al. Relevance of
the rates of PCNA, Ki-67 and p53 expression according to
the epithelial compartment in cervical lesions. Pathologica,
2001;93:189–95.
33. de Putte GV, Kristensen GB, Lie K, Baeklandt M, Holm R.
Cyclins and proliferation markers in early squamous
cervical carcinoma. Gynecol Oncol 2004;92:40–6.
34. Zielinski GD, Snijders PJF, Rozendaal L et al. The presence
of high-risk HPV combined with specific p53 and
p16INK4A expression patterns points to high-risk HPV as
the main causative agent for adenocarcinoma in situ and
adenocarcinoma of the cervix. J Pathol 2003;201:535–43.
35. Sanders DS, Perry I, Hardy R, Jankowski J. Aberrant
P-cadherin expression is a feature of clonal expansion in
the gastrointestinal tract associated with repair and
neoplasia. J Pathol 2000;190:526–30.
36. Shimoyama T, Hirohashi S. Expression of E- and P-cadh-
erin in gastric carcinoma. Cancer Res 1991;51:2185–92.
37. Han AC, Soler AP, Tang CK, Knudsen KA, Salazar H.
Nuclear localization of E-cadherin expression in Merkel
cell carcinoma. Arch Pathol Lab Med 2000;124:1147–51.
P-cadherin in cervical glandular lesions 93
Cytopathology 2005, 16, 88–93 ª 2005 Blackwell Publishing Ltd
